Detalles de la búsqueda
1.
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate.
Mol Cancer Ther
; 22(6): 765-777, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37042205
2.
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
J Immunother Cancer
; 11(4)2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37068796
3.
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.
Mol Cancer Ther
; 17(11): 2389-2398, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30093567
4.
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
Mol Cancer Ther
; 14(3): 692-703, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25589493
5.
Glucose kinetics in the collagen-induced arthritis model: an all-in-one model to assess both efficacy and metabolic side effects of glucocorticoids.
PLoS One
; 9(9): e98684, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25181348
6.
Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.
Mol Cancer Ther
; 13(11): 2618-29, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25189543
7.
CYP7B expression and activity in fibroblast-like synoviocytes from patients with rheumatoid arthritis: regulation by proinflammatory cytokines.
Arthritis Rheum
; 52(3): 770-8, 2005 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15751070
Resultados
1 -
7
de 7
1
Próxima >
>>